治疗前肠道微生物组多样性与功能与HIV感染者N-803治疗后细胞毒及自然杀伤细胞免疫应答相关
该探索性纵向宏基因组研究分析10例ART抑制的HIV感染者N-803治疗前后四个时间点的粪便微生物组,发现总体分类和功能多样性无显著变化,但有益微生物分类群和通路在N-803后名义富集;基线微生物多样性较高与更强的CD8+和NK细胞活化及直肠HIV RNA+细胞频率降低相关。
要点
- N-803治疗后总体微生物多样性未显著改变,但有益菌群和通路名义富集。
- 基线微生物多样性较高与更强的CD8+和NK细胞活化相关。
- 基线多样性较高与直肠HIV RNA+细胞频率降低相关。
核心结论
- 在有限样本的1B期临床研究中,免疫治疗前的肠道微生物组多样性可能影响宿主对N-803的免疫应答。
研究设计与样本
- 探索性纵向宏基因组研究,分析10例ART抑制的HIV感染者在N-803治疗前、中、后四个时间点的粪便微生物组。
主要发现
- 总体分类和功能多样性未显著变化,但有益微生物分类群和通路在N-803后名义富集。
- Faecalibacterium prausnitzii相对丰度在N-803后名义增加,组氨酸降解通路(常与促炎黏膜状态相关)减少。
- 基线微生物多样性较高与更强的CD8+和自然杀伤(NK)细胞活化及直肠HIV RNA+细胞频率降低相关。
- MaAsLin2分析识别出产短链脂肪酸(SCFA)的分类群和通路与免疫活化标志物增加之间的潜在重要关联。
临床怎么用
- 基线肠道微生物组多样性可能作为预测HIV免疫治疗应答的潜在生物标志物。
- 该结果提示可进一步研究基于微生物组的策略以改善HIV治愈尝试。
局限性
- 样本量有限(10例),属于探索性1B期临床研究。
- 观察到的微生物分类群和通路变化为名义富集,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: N-803, an IL-15 superagonist, is currently being studied in clinical trials as a treatment to reverse HIV latency. However, its effects on the gut microbiome are not well understood. METHODS: In this exploratory longitudinal metagenomic study, we analyzed fecal microbiomes from 10 ART-suppressed people with HIV at four different timepoints before, during, and after N-803 treatment. RESULTS: Overall taxonomic and functional diversity did not change significantly, yet beneficial microbial taxa and pathways were nominally enriched after N-803. Specifically, the relative abundance of Faecalibacterium prausnitzii showed a nominal increase after N-803, whereas histidine degradation pathways, often associated with pro-inflammatory mucosal state, decreased. A higher baseline microbial diversity correlated with stronger CD8+ and natural killer (NK) cells activation and reduced frequency of rectal HIV RNA+ cells. MaAsLin2 analyses further identified potentially important associations between short-chain fatty acid (SCFA)-producing taxa and pathways with increased immune activation markers. CONCLUSIONS: These findings in a limited Phase 1B clinical study suggest that gut microbiome diversity prior to immunotherapy may influence host response. These results provide a basis for further investigation into microbiome-based strategies to improve efforts to cure HIV.
引用
- Chakrawarti A, Cromarty RT, Basting CM, et al. Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV. Clin Infect Dis. 2026. PMID: 42402338. doi:10.1093/cid/ciag369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。